The FDA granted accelerated approval for sibeprenlimab-szsi to reduce proteinuria for adults with primary immunoglobulin A ...
Vixarelimab showed significant symptom relief and disease progression reduction in prurigo nodularis compared with placebo across all doses. A phase 2b trial found vixarelimab rapidly reduced itch and ...
Nektar Therapeutics is advancing Rezpeg in atopic dermatitis and alopecia areata. Click here for key insights on NKTR's ...
Pharmaceutical Technology on MSN
Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs
Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.
Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback